ATB Therapeutics Announces Appointment of Dr. Torsten Dreier as Chief Development Officer and Opening of New R&D Hub in Gent
Marche-en-Famenne and Ghent, Belgium – June 10th, 2025 – ATB Therapeutics, a pioneering biopharmaceutical company specializing in innovative antibody-based therapies for oncology and immunology, is pleased to announce two major developments:
- The appointment of Dr. Torsten Dreier as Chief Development Officer (CDO)
- The opening of an additional research and development hub in Gent, Belgium
Dr. Dreier, co-founder of argenx, brings over 30 years of experience in the pharmaceutical industry, having held key roles in the development of antibody-based drugs at leading biotech companies including Micromet, Ablynx, argenx, and Agomab. His deep expertise will be instrumental in advancing ATB Therapeutics’ pipeline of novel therapeutic formats, particularly through the company’s proprietary plant-based ATBioFarm technology.
“We are thrilled to welcome Torsten Dreier to our team,” said Bertrand Magy, CEO of ATB Therapeutics. “His extensive experience and proven leadership in drug development will be invaluable as we continue to innovate and expand our capabilities.”
Dr. Dreier shared his perspective on joining the company: “I’m excited to join ATB Therapeutics at such a pivotal time. The company’s unique approach to delivering novel payloads through its ATBioFarm platform offers a promising avenue to push the boundaries of antibody-drug conjugate development in a meaningful way.”
In tandem with this strategic appointment, ATB Therapeutics is proud to unveil its new R&D hub located in the VIB Bio-Incubator in Gent—a state-of-the-art facility designed to foster biotech innovation. This expansion marks a significant milestone in the company’s growth and commitment to accelerating the development of transformative therapies.
“The new hub in Gent represents a significant milestone for ATB Therapeutics,” said Mark Throsby, Executive Chairman. “Gent is renowned for its concentration of high-level biotech companies and as a hub where top talent converges. This environment will provide us with unparalleled opportunities to build a world-class scientific team and drive our research and development efforts forward.”
ATB Therapeutics remains steadfast in its mission to address high unmet medical needs through next-generation weaponized antibody therapies. These latest developments underscore the company’s dedication to advancing the fields of oncology and immunology.
For more information, please visit www.atbtherapeutics.com
About ATB Therapeutics
Founded in 2018, ATB Therapeutics is a pioneering biotechnology company based in Marche-enFamenne, Belgium, dedicated to the discovery and development of novel antibody therapies. Leveraging a proprietary technology platform based on plant molecular farming, ATB Therapeutics aims to deliver targeted solutions to high unmet medical needs, including oncology and autoimmune diseases, through innovative, next-generation of weaponized antibody treatments.
About VIB Bio-incubator
The new VIB Bio-Incubator is located along the E40 near Eiland Zwijnaarde. With a BREEAM certification and CO₂-neutral operation, the building marks a significant step in VIB’s commitment to sustainable progress. Interested startups can visit the VIB Bio-Incubator website for more information.
For Media Inquiries, Contact:
ATB Therapeutics
Dr Bertrand Magy, CEO
Email: [email protected]